carl zeiss meditec ag company presentation

Carl Zeiss Meditec AG

Company Presentation2013/2014

Pioneering Medical TechnologyCarl Zeiss Meditec AG

Carl Zeiss Meditec AG

With innovations for ophthalmology and microsurgery, the Medical Technology business group of ZEISS is contributing to progress in medicine. Our products and solutions aim to help physicians to improve patient outcomes and their patients’ quality of life.

Improving the quality of live

2

A world-leading medical technology company

Comprehensive systems to diagnose and treat eye diseases

Complete solutions for visualisation, microscopes for spinal, neuro/ENT, ophthalmic and dental procedures, IORT*

Ophthalmology Microsurgery

We drive progress in medicine, enabling doctors to achieve the best possible outcomes for their patients.

Results 2012/2013:

Revenue: € 906.4 mn; Growth: 5.2 %

EBIT: € 133.9 mn; EBIT margin: 14.8 %

Headquarters in Jena, Germany

More than 2,500 employees worldwide

Listed on the TecDAX

Around 65 % of the shares held by ZEISS

Carl Zeiss Meditec AG

At a GlanceCarl Zeiss Meditec AG

* IORT: Intraoperative Radiotherapy

3

Executive Board

At a GlanceCarl Zeiss Meditec AG

Dr. Ludwin Monz (President & CEO) Dr. Christian Müller (CFO) Thomas Simmerer (CSO)

Carl Zeiss Meditec AG

From left to right: Dr. Ludwin Monz, Thomas Simmerer, Dr. Christian Müller

4

Broad Product PortfolioWe Offer Our Customers an Extensive Portfolio

Carl Zeiss Meditec AG

Private practitioners

OphthalmicSystemsSales FY 12/13:€ 391 mn

Clinics

Surgical Oncology

Ambulatorysurgerycenters

Hospitals

Cataract Surgery

Visualisation & Microsurgery

Glaucoma & RetinaDiagnosis & Therapy

Corneal Refractive Surgery

Customers SBUSegments Products

MicrosurgerySales FY 12/13:€ 394.2 mn

SurgicalOphthalmologySales FY 12/13:€ 121.3 mn

5

Carl Zeiss Meditec AG

Americas APACEMEA

36.1% 33.9% 29.9%

Growth & Revenue Split by RegionsFY 2011/12 FY 2012/13

Results at a Glance (FY 12/13)All Regions and Strategic Business Units Contributed To Growth

Growth & Revenue Split by SBUs* FY 2011/12 FY 2012/13

Microsurgery OphthalmicSystems

Surgical Ophthalmology

+ 12.6 %+ 4.0 %+ 4.2 %

13.4%43.5% 43.1%

* SBU: Strategic Business Unit

+ 7.8 % + 5.9 % + 1.4 %

6

Financials at a Glance (FY 12/13)Carl Zeiss Meditec AG

Revenue

€ 906.4 mnIncrease compared to FY 11/12: 5.2 %

EBIT

€ 133.9 mnResult

€ 93.5 mn*

EBIT-Margin

14.8 %

Carl Zeiss Meditec AG 7

* Consolidated net income after non-controlling interests

Success StoryNumbers Defining Growth

70 % Carl Zeiss Meditec holds 70 percent market share of surgical microscopes for neurosurgery

Carl Zeiss Meditec AG

4 millionTo date, more than 4 million surgeries around the world have been performed with OPMI® Pentero®

and OPMI® PENTERO® 900

8

Success StoryNumbers Defining Growth

Carl Zeiss Meditec AG

50 %Today, more than half of all Optical Coherence Tomography Systems (OCT) in ophthalmological practicesare ZEISS OCTs

75 %Around 75 percent of all cataract patients come into contact with a product from ZEISS during their treatment

9

10.7 %In FY 12/13, Carl Zeiss Meditec AG has invested 10.7 percent of its revenue in Research & Development

Success StoryNumbers Defining Technology Leadership

1.8 millimetersAn incision of 1.8 millimeters is all that is needed to insert a ZEISS intraocular lens into a patient’s eye

Carl Zeiss Meditec AG

Lens diameter(optics)6 mm

Incision length1.8 mm

10

Dividend | Total Dividend distributedin € | in € million

Additional special dividendRegular dividend

Dividend reflects Company‘s successInvestment in the Future of Health Care

Carl Zeiss Meditec AG 11

* Propose to the Annual General Meeting

0.18 0.18 0.22 0.30 0.40 0.45*

0.33

14.6 14.6

44.7

24.4

32.336.6

07/08 09/10 11/1208/09 10/11 12/13

0.45*

Recognizing OpportunitiesMeeting Today‘s Challenges

Global Mega Trends

Carl Zeiss Meditec AG 12

Global marketDemographic Change

Technological Change

Carl Zeiss Meditec AG

Demographic ChangeThe Proportion of Older People is Growing

13

Carl Zeiss Meditec AG

Demographic ChangeComprehensive Solutions for TypicalAge-related Diseases

„The proportion ofolder people in theoverall population isgrowing in many partsof the world. We offercomprehensivesolutions for thediagnosis andtreatment of typicalage-related diseases.“

Dr. Ludwin Monz

President & CEO

14

Demographic ChangeInnovations for Age-related Diseases

15Carl Zeiss Meditec AG

CALLISTO eye ® assists cataract surgeons with the precision alignment of IOLs

40 %Lens clouded by cataract

Vision with cataractNormal vision

of the population will develop cataracts

15

Demographic change

Technological change

Technological ChangeThe Medical Sector is Rapidly Changing

Global market

Carl Zeiss Meditec AG 16

Carl Zeiss Meditec AG

Technological ChangeExpanding the Possibilities of Medicine

„The entire medicalsector is rapidlybecoming digitized. And we, as one of thefront runners, areplaying an activerole.“

Dr. Christian Müller

Member of theManagement Board

17

100 Years of Leadership in Medical TechnologyGold Standard Products Defining the Market

OPMI® HFA™

PerimeterOCT 1 IOLMaster®

VisuMax ®

FemtosecondSystem

Slit lamp

Pace-setting innovation for more than 100 years

Carl Zeiss Meditec AG 18

Carl Zeiss Meditec AG

Patients have high expectations of clinical outcomes

Technological LeadershipPioneering Refractive Laser Technology

Minimally-invasive refractive laser surgery with ReLEx® smile

ReLEx® smile: Minimally invasive treatment methods set new standards in refractive surgery

19

Technological LeadershipThe Next Generation of Surgical Microscopes

Brilliant visualization in Neurosurgerywith OPMI® PENTERO® 900

Carl Zeiss Meditec AG 20

Technological LeadershipDisruptive Innovation in Breast CancerTreatment

Innovative breast cancer treatmentwith INTRABEAM®

Carl Zeiss Meditec AG 21

Global market

Global MarketThe World is Converging

Demographic change

Technological change

Carl Zeiss Meditec AG 22

Global MarketWe Are Well Aware of Our Customers‘ Demands

Carl Zeiss Meditec AG

„Through our global network we are wellaware of ourcustomers‘ demands. We use thisknowledge to definestandards which wethen put into practicethrough international training courses.“

Thomas Simmerer

Member of theManagement Board

23

Spain:Madrid

US:Dublin

Japan:Tokyo

Germany:JenaBerlinOberkochenMunich

France:Marly-le-RoiLa RochelleParis

Company sites of the Carl Zeiss Meditec Group Production, sales, service, R&D

Sales and Service sites of the Carl Zeiss Meditec Group

Sales and Service sites of the ZEISS Group

Global PresenceMore Than 30 Sites Worldwide in Every Major Market

Carl Zeiss Meditec AG 24

Global KnowledgeSharing knowledge through worldwide training with the ZEISS ACADEMY

Employee training in Jena

Training workshop in Hong Kong with customers

Carl Zeiss Meditec AG 25

ChinaSouth

East Asia

India

Brazil

Mexico

R&D Centers in rapidly developing economies

Global InnovationResearch and Development in RapidlyDeveloping Economies

Carl Zeiss Meditec AG 26

Our AspirationEvery Patient in Our Segment is Treated With One of our Products

Our Aspiration

Carl Zeiss Meditec AG

“We want to make our products and services

accessible and relevant to doctors’ needs

all over the world –so that in our segments

every patient can be treated with one of our products.”

27

Corporate Social ResponsibilityEyesight is Not „Normal“ For Everyone

Source: D. Pascolini, S.P. Mariotti, “Global estimates of visual impairment”, Br. J. Ophthalmol. 96, 614 - 618 (2012).

285 million people are visually impaired

1-2 million people go blind per year

39 million people are blind

Carl Zeiss Meditec AG 28

Corporate Social ResponsibilitySupporting Doctors to Bring Highest Level ofClinical Care to Their Patients All Over The World

Support for the Fellowship program of the International Council of Ophthalmology(ICO): In November 2013, ZEISS invited five of the fellows

Carl Zeiss Meditec AG 29

Goal of VISION 2020:

“By 2020, the primary causes of preventable blindness will be eliminated to ensure that everyone around the world receives a right to sight.”

Initiated by the World Health Organization (WHO) and the International Agency for the Prevention of Blindness (IAPB) in 1999

The ZEISS Medical Technology Business Group supports the VISION 2020 initiative together with other NGO’s, professional associations, ophthalmic institutes and companies

Corporate Social ResponsibilityThe VISION 2020 Initiative Will Spare Around 100 Million People From Blindness

Carl Zeiss Meditec AG 30

Medical Technology Business GroupFirmly anchored in the ZEISS Group

Medical and Research Solutions Industrial Solutions Lifestyle

Products

Busi

ness

Gro

ups

Medical Technology Microscopy Semiconductor

Manuf. Tech.Industrial Metrology

Camera Lenses, Sports Optics, Planetariums

Vision Care

Carl Zeiss AG

Mar

kets

Rev

enue

FY12

/13

€ 1.032 m* € 629 m € 934 m € 528 m € 195 m € 841 m

Vision Care

Carl Zeiss Meditec AG

* The values deviate from the published figures of Carl Zeiss Meditec Group as a result of different consolidation models.

31